Peptigrade

Growth Hormone Axis

Sermorelin

Sermorelin acetate — GHRH(1-29)-NH₂, synthetic growth-hormone-releasing-hormone analog·Also known as: GHRH(1-29), Geref, GRF(1-29), Somatorelin, Sermorelin acetate

FDARegulatory status

Historically FDA-approved. Geref (sermorelin acetate, Serono) received FDA diagnostic approval in 1990 and therapeutic approval in 1997 for idiopathic pediatric growth hormone deficiency. Commercial production was discontinued in 2008 for manufacturing reasons, not safety or efficacy. No FDA-approved sermorelin product is currently marketed. The molecule remains available in the United States only as a compounded preparation (503A) or as a research chemical.

WADARegulatory status

Prohibited at all times (S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics; specifically S2.2 GHRHs / GHRH agonists) on the 2026 WADA Prohibited List (in force January 1, 2026). USADA explicitly flags sermorelin in athlete advisories.

Regulatory note ·Sermorelin is the shortest fully active fragment of human GHRH (1-29) and was the original reference GHRH-analog therapeutic. Geref (Serono) was withdrawn from the US market in 2008 for manufacturing-related reasons — not for safety or efficacy concerns — and sermorelin has not been re-registered under any brand since. Current US access is through 503A compounding pharmacies and research-chemical channels; no Phase 3 RCT in adults for wellness, anti-aging, body-composition, or sleep endpoints has ever been completed or peer-reviewed. The pediatric GHD literature supporting the 1997 approval was summarized in Prakash 1999 and Walker 2008 (PMID 18031173); those reviews remain the core clinical evidence base. WADA's S2.2 listing covers all GHRH agonists including sermorelin, CJC-1295, and tesamorelin.

§ The quick take

TL;DR · Editor’s summary

Sermorelin is the reference GHRH(1-29) analog and the only GHRH agonist other than tesamorelin to have ever carried an FDA label. Geref (Serono) was approved in 1990 as a diagnostic GH-stimulation agent and in 1997 as a therapeutic for idiopathic pediatric growth hormone deficiency, based on six-month and 36-month pediatric trials reviewed in Prakash 1999 (BioDrugs 12(2)) and Walker 2008 (PMID 18031173). IV sermorelin at 1 μg/kg produces rapid, relatively specific GH release with a 30–60 minute peak and fewer false-positive responses than insulin-tolerance or L-dopa provocation — the cleanest use case in the peptide's evidence file. The commercial product was discontinued in 2008 for manufacturing reasons, not safety or efficacy; the molecule has not been re-registered since.

Current US availability is through 503A compounding pharmacies and research channels. The proximal pharmacology is well-characterized: binds pituitary GHRH-R, activates the canonical Gαs/cAMP/PKA/CREB cascade, triggers voltage-gated calcium influx and vesicular GH exocytosis, and — critically — preserves pulsatile GH physiology because the ~5–10 minute plasma half-life forces dosing to ride on top of endogenous somatostatin feedback rather than replacing it. This is the feature wellness clinics cite when positioning sermorelin against recombinant GH. The honest gap: no randomized placebo-controlled trial of sermorelin for adult wellness, body-composition, sleep, or anti-aging endpoints has been completed.

Adult-use claims substantially outrun the adult-data file. The pediatric approval indications are B-graded because the commercial product is off-market and the modern GH-stimulation workup has migrated toward macimorelin and glucagon. WADA-prohibited at all times as a GHRH agonist (S2.2).

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Sermorelin, sorted by strength of evidence.

B

Diagnostic provocation for pediatric growth hormone deficiency

Promising

FDA-approved indication (1990 diagnostic label). IV sermorelin at 1 μg/kg produces rapid, relatively specific GH release with a 30–60 minute peak and fewer false-positive responses than insulin-tolerance or L-dopa provocation (Walker 2008, PMID 18031173; Prakash 1999, BioDrugs). The directly on-target, regulator-reviewed use — graded B rather than A because the newer GH-stimulation literature has migrated toward macimorelin and glucagon for adult testing, and sermorelin-specific head-to-head trials against those comparators are thin.

6 studiesUpdated 2026-04-20
B

Pediatric idiopathic growth hormone deficiency (therapeutic)

Promising

FDA-approved indication (1997 therapeutic label for Geref). Six-month and 36-month treatment studies reviewed in Prakash 1999 (Springer BioDrugs 12(2)) and Walker 2008 (PMID 18031173) showed significant increases in both stimulated GH and growth velocity in GHD children. Not A-graded because the commercial product has been off-market since 2008, no contemporary replication trial has been published, and recombinant GH remains the current pediatric GHD standard of care.

5 studiesUpdated 2026-04-20
D

Adult growth hormone insufficiency (symptomatic)

Weak

Small adult studies showed sermorelin can raise GH and IGF-1 in adults with age-related decline (summarized in Walker 2008 and Prakash 1999), but no randomized, placebo-controlled Phase 3 trial has measured symptomatic or functional endpoints (fatigue, cognition, quality of life) in adult-onset GHD or somatopause. The clinical-practice use in anti-aging medicine substantially exceeds the peer-reviewed evidence.

3 studiesUpdated 2026-04-20
Ins.

Body composition (lean mass / fat mass)

Insufficient

No controlled human trial with DEXA or MRI body-composition as a primary endpoint and sermorelin as the intervention is in the peer-reviewed literature. Downstream expectations are extrapolated from recombinant GH and tesamorelin (lipodystrophy) rather than from on-molecule evidence.

0 studiesUpdated 2026-04-20
Ins.

Sleep architecture / slow-wave sleep

Insufficient

Mechanistically plausible through nocturnal GH physiology — endogenous GHRH pulses increase during slow-wave sleep — but no polysomnography-endpoint randomized trial with sermorelin is in the peer-reviewed literature. The common wellness-clinic claim that sermorelin improves deep sleep does not have a supporting RCT.

0 studiesUpdated 2026-04-20
Ins.

HIV-associated lipodystrophy

Insufficient

Investigated in early exploratory work (Walker 2008 cites this as an adjacent area), but the indication was ultimately pursued and approved with tesamorelin (Egrifta, 2010), not sermorelin. No positive Phase 2/3 sermorelin-on-molecule readout for this indication.

1 studiesUpdated 2026-04-20
B

Safety / tolerability at short-term exposure

Promising

Clinical-use experience across the 1990 diagnostic and 1997 therapeutic approvals established a favorable short-term profile: mild, transient adverse events, rare injection-site reactions and flushing, no serious AEs leading to regulatory action. Lower anti-GH antibody formation than exogenous GH (Prakash 1999). Long-term adult exposure data beyond the pediatric therapeutic window are thin.

6 studiesUpdated 2026-04-20

§ Why this grade

Sub-scores for this outcome.

Diagnostic provocation for pediatric growth hormone deficiency

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

5 / 5

GHRH-R / Gαs / cAMP / PKA / CREB / GH1 cascade is canonical endocrinology (Muller 1999, Physiological Reviews; Salvatori 2025 GHRH-R review). Calcium and phospholipase C arms are characterized. Preservation of pulsatile physiology is a direct consequence of the 5–10 minute half-life. This is the best-understood mechanism in any GHRH analog.

Human studies (count + quality)

3 / 5

FDA approval program (Geref) supported by pediatric diagnostic and therapeutic trials reviewed in Prakash 1999 (BioDrugs 12(2)) and Walker 2008 (PMID 18031173). Diagnostic label 1990, therapeutic label 1997. No contemporary replication since 2008 discontinuation, and the modern adult GH-stimulation workup has migrated toward macimorelin and glucagon comparators. Pediatric diagnostic use is the highest-quality on-molecule evidence in the file.

Effect vs placebo

4 / 5

IV sermorelin at 1 μg/kg produces rapid GH release in GH-sufficient children and attenuated response in GHD — the diagnostic specificity that underpinned the 1990 FDA approval. Dose-responsive, directly on-target, with fewer false positives than older provocation tests. Not a 5 because sermorelin vs modern comparators (macimorelin, glucagon) head-to-head RCT data are thin.

Long-term safety data

3 / 5

Pediatric therapeutic exposure in the 1997 approval program extended to 36 months with no serious safety concerns identified. Lower anti-GH antibody formation than recombinant GH (Prakash 1999). Long-term adult surveillance cohort data do not exist — current wellness-clinic use exceeds the formal long-term adult-exposure evidence.

Side effect profile

4 / 5

Clinical experience across the diagnostic and therapeutic labels established mild, transient adverse events (injection-site reactions, flushing, occasional headache). No serious AEs led to regulatory action. Commercial discontinuation in 2008 was explicitly manufacturing-related, not safety-related (Wikipedia Sermorelin; Walker 2008). Feedback-intact mechanism limits risk of GH excess.

Regulatory status

3 / 5

Historically FDA-approved (Geref, 1990 diagnostic / 1997 therapeutic); commercial product discontinued 2008. No currently marketed FDA-approved product. Accessible in the United States only through 503A compounding pharmacies and research channels. WADA-prohibited at all times under S2.2 on the 2026 Prohibited List. Higher than a 1 because the approval history is real; lower than a 5 because there is no marketed product today.

§ What the science says

How Sermorelin
works.

The scientific explanation of the molecule and its proposed mechanism, with a plain-English translation — written at an 8th-grade reading level — in the teal callouts below each section. Every claim is linked to a primary source below.

What it is

Sermorelin is a 29-amino-acid synthetic polypeptide comprising residues 1–29 of endogenous human growth-hormone-releasing hormone (molecular formula C₁₄₉H₂₄₆N₄₄O₄₂S, MW 3,357.9 Da, CAS 86168-78-7). The sequence — Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ — is identical to native GHRH(1-29) with one modification: C-terminal amidation that confers resistance to carboxypeptidase degradation. GHRH(1-29) is the shortest fragment of the 44-amino-acid native hormone that retains full agonist activity at the GHRH receptor, and it was the backbone later engineered into both tesamorelin (FDA-approved 2010 for HIV lipodystrophy) and CJC-1295 (long-acting DAC analog). Sermorelin's plasma half-life is approximately 5–10 minutes, which is the feature that preserves pulsatile GH physiology: each injection ramps GH transiently and then clears before somatostatin and IGF-1 negative feedback are overridden. Geref (Serono) was the FDA-approved product form from 1990 (diagnostic) and 1997 (therapeutic) until commercial discontinuation in 2008.

In plain English

Sermorelin is a synthetic 29-amino-acid peptide identical to the first 29 amino acids of the body's natural growth-hormone-releasing hormone (GHRH) — the signal that normally tells the pituitary gland to release growth hormone. The 29-amino-acid version is the shortest piece of GHRH that still works at full strength. One small modification makes it more stable in the bloodstream. Because it clears from the blood in only about 5 to 10 minutes, each dose causes a brief spike of growth hormone and then disappears before the body's natural braking systems are overwhelmed. This preserves the pulsatile rhythm of GH release. It was marketed as Geref (Serono) from 1990 to 2008. CJC-1295 and tesamorelin were both built from the same backbone.

How it works

  1. 01

    GHRH-R agonism at pituitary somatotrophs

    Sermorelin binds the extracellular N-terminal domain of the growth-hormone-releasing-hormone receptor (GHRH-R), a class B II (secretin-family) Gαs-coupled GPCR expressed predominantly on anterior-pituitary somatotrophs. The human receptor is 423 residues with conserved cysteines and an N-glycosylation site. Sequence identity with native GHRH(1-29) gives sermorelin full agonist efficacy and preserved selectivity for GHRH-R over related peptide-hormone receptors (Walker 2008, PMID 18031173; GHRH-R signaling review — Salvatori 2025, Rev Endocr Metab Disord).

    In plain English

    It activates the pituitary's growth-hormone release button

    Sermorelin's sequence is identical to natural GHRH(1-29), so it binds the same receptor on pituitary cells — called GHRH-R — that the body's own GHRH uses. This receptor sits on the pituitary cells that produce and store growth hormone. Because the sequence matches the body's own signal exactly, sermorelin is a 'full agonist' — it activates the receptor just as efficiently as the natural signal, with no crossover to other hormone receptors.

  2. 02

    Gαs / cAMP / PKA / CREB signaling cascade

    Receptor activation dissociates Gαs from Gβγ, stimulates membrane-bound adenylyl cyclase, elevates intracellular cAMP, and activates protein kinase A. PKA phosphorylates CREB, which — together with coactivators p300 and CBP — binds cAMP-response elements in the GH1 promoter and enhances GH gene transcription. CREB also upregulates the pituitary-specific transcription factor Pit-1, amplifying GH expression (Muller 1999, Physiological Reviews 79:511). This is the canonical endocrinology cascade that sermorelin was engineered to reproduce.

    In plain English

    Binding the receptor triggers a chain reaction that tells cells to make more GH

    When sermorelin docks on its receptor, it sets off a chain reaction inside the pituitary cell: the receptor activates an enzyme that makes a chemical messenger called cAMP, cAMP activates a protein called PKA, PKA activates a gene switch called CREB, and CREB turns on the growth hormone gene. CREB also turns on another protein that keeps the GH gene active over time. This is the standard step-by-step signal chain the body uses to make growth hormone — sermorelin reproduces it faithfully.

  3. 03

    Calcium influx and exocytic GH release

    cAMP elevation opens voltage-gated Ca²⁺ channels in the somatotroph plasma membrane; the Ca²⁺ influx drives vesicular exocytosis of pre-formed GH granules. GHRH-R activation also engages phospholipase C — IP₃ releases intracellular Ca²⁺ from ER stores, while DAG activates PKC. cAMP additionally modulates K⁺ channel activity, contributing to the synchronized electrical excitability that underlies pulsatile release (Muller 1999; Salvatori 2025 hypothalamic-GHRH review).

    In plain English

    The signal opens calcium channels to release stored GH quickly

    The chain reaction also opens calcium channels in the cell wall. Calcium rushes in and triggers tiny storage pouches full of pre-made GH to release their contents into the bloodstream. A parallel pathway pulls calcium from storage inside the cell as well. The result: rapid release of growth hormone that had already been made and stored, producing the GH peak seen 30–60 minutes after a sermorelin injection.

  4. 04

    Acute vs chronic somatotroph effects

    Acutely, sermorelin drives rapid mobilization of pre-formed GH granules and Ca²⁺-dependent exocytosis. Chronically — demonstrated over 6- and 36-month pediatric treatment courses in the Geref approval program (Prakash 1999, BioDrugs; Walker 2008, PMID 18031173) — it upregulates GH gene transcription, increases GH mRNA, replenishes cellular GH stores, and may promote somatotroph proliferation and differentiation. Walker 2008 argues this is why a GHRH-axis agonist can produce durable effects on growth velocity rather than just transient GH spikes.

    In plain English

    Short-term it releases GH fast; long-term it may replenish the pituitary's GH supply

    In the short term, sermorelin triggers rapid release of stored GH from the pituitary. With ongoing treatment — as shown in the six-month and 36-month pediatric trials — the pituitary also ramps up how much GH it makes. Over time, the pituitary cell may even grow and divide more. This is why a GHRH-based drug can produce lasting improvements in growth velocity rather than just a quick spike that fades.

  5. 05

    Preservation of pulsatile physiology

    The feature that differentiates sermorelin from long-acting GHRH analogs (CJC-1295 DAC) and from exogenous recombinant GH is its ~5–10 minute plasma half-life. Sermorelin rises, triggers a GH pulse, and clears before the downstream somatostatin and IGF-1 negative-feedback arms are saturated. The result is a physiologic pulsatile GH profile (approximately every 3 hours at endogenous frequency, more frequent during slow-wave sleep) rather than the tonic elevation produced by DAC-conjugated analogs (Walker 2008; Prakash 1999). Whether pulsatile GH produces clinically different downstream effects from tonic GH at equivalent AUC remains an open mechanistic question, but the physiology is why sermorelin has been positioned as a 'feedback-intact' GH stimulator.

    In plain English

    Its short half-life preserves the body's natural GH rhythm

    Sermorelin clears from the blood in about 5–10 minutes. Each injection causes a GH pulse and then disappears before the body's 'braking' signals overwhelm the system. The result is a natural-looking, pulsatile GH pattern — spikes every few hours, more frequent during deep sleep — rather than the constant flat elevation produced by long-acting analogs like CJC-1295 DAC or by injected recombinant GH. Whether pulsatile vs constant GH leads to different clinical outcomes at the same total dose is still an open question, but the pulsatile profile is the main reason wellness clinics position sermorelin differently from other GH-raising approaches.

  6. 06

    Intact feedback and ceiling on GH exposure

    Because sermorelin acts upstream of the pituitary, its effect is bounded by intact somatostatin and IGF-1 negative feedback. Supraphysiologic GH levels of the kind seen with recombinant GH overdosing are difficult to achieve with sermorelin — the pituitary stops responding when endogenous inhibitors rise. This feedback ceiling is the theoretical safety argument behind sermorelin's lower anti-GH-antibody formation rate and its historical use in pediatric GHD (Prakash 1999). It does not, however, mean the compound is inert against long-term IGF-1-axis concerns — it means those concerns apply through different channels than with direct GH administration.

    In plain English

    The body's own safety brakes cap how high GH can go

    Because sermorelin acts on the pituitary (upstream) rather than injecting GH directly, the body's natural feedback brakes still work. When GH and IGF-1 rise, the hypothalamus sends a 'stop' signal — somatostatin — to the pituitary, which then stops responding to sermorelin. This makes it very hard to reach the dangerously high GH levels that can happen with recombinant GH misuse, and it explains why sermorelin produced fewer immune antibodies than injected GH in the original trials. It doesn't eliminate long-term IGF-1 concerns entirely — it just routes them through a different mechanism.

  7. 07

    What is NOT known about the mechanism

    Human pharmacokinetics have been characterized for the acute IV/SC setting but not well-described under chronic long-term adult dosing. The long-term oncologic risk of chronic IGF-1 elevation (breast, prostate, colorectal epidemiologic associations with serum IGF-1) has not been prospectively tested in adult sermorelin cohorts. Whether the pulsatile pattern preserved by short-acting GHRH agonism produces clinically different long-term outcomes than the tonic pattern produced by long-acting DAC analogs is an open question that no head-to-head human trial has addressed. Immunogenicity (anti-sermorelin antibodies) is reported as lower than with recombinant GH but is not zero, and long-term immunogenicity in compounded-pharmacy preparations has no formal surveillance program.

    In plain English

    What we still don't know about how it works long-term in adults

    How the drug behaves in adults using it for months or years is not well characterized. The long-term cancer risk from years of elevated IGF-1 — a concern linked to breast, prostate, and colorectal cancer in population studies — has not been studied in adult sermorelin users. No trial has directly compared pulsatile (sermorelin) vs constant (CJC-1295 DAC) GH exposure to see if it actually matters for real clinical outcomes. And the antibody risk in compounded-pharmacy preparations — which vary in purity from one pharmacy to another — has no formal tracking program.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Diagnostic GH-stimulation testing for pediatric GHD

    FDA-approved 1990 (Geref diagnostic label); Walker 2008 (PMID 18031173), Prakash 1999 (BioDrugs)

  • Idiopathic pediatric growth hormone deficiency — therapeutic

    FDA-approved 1997 (Geref therapeutic label); six-month and 36-month pediatric treatment studies in the approval program

  • Adult GH insufficiency / age-related GH decline

    Small open-label and uncontrolled studies summarized in Walker 2008 and Prakash 1999; no Phase 3 RCT

  • Combination GH-stimulation testing (sermorelin + arginine)

    USADA athlete advisory and older endocrinology literature; not the current standard-of-care provocation for adults

  • Body composition, recovery, sleep, anti-aging (wellness clinic indications)

    Widely used off-label in compounded-pharmacy practice; no on-molecule controlled human trial for any of these endpoints

  • HIV-associated lipodystrophy

    Adjacent area of early interest; indication ultimately pursued and FDA-approved with tesamorelin (2010), not sermorelin

  • Immunomodulation (cyclophosphamide antagonism)

    Animal-model observations referenced in the IUPHAR/BPS entry for sermorelin; no human trial

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    No randomized, placebo-controlled Phase 3 trial of sermorelin in adults for wellness, body-composition, sleep, cognition, or anti-aging endpoints has ever been completed or peer-reviewed. The adult-use claims in compounded-pharmacy practice substantially exceed the adult-data file.

  • !

    No contemporary replication of the pediatric GHD therapeutic trials has been conducted since Geref went off-market in 2008. The current clinical evidence base for the 1997 approval remains the original Serono program and the 1999 / 2008 review articles.

  • !

    Long-term oncologic risk of chronic IGF-1 elevation under multi-year sermorelin exposure in adult populations has not been studied. The epidemiologic IGF-1 / cancer associations (breast, prostate, colorectal) are not compound-specific but would apply if chronic IGF-1 elevation is achieved.

  • !

    Head-to-head comparisons of pulsatile (sermorelin) vs tonic (CJC-1295 DAC) GH exposure for any downstream clinical endpoint in humans do not exist. The mechanistic argument for pulsatility is plausible but untested at endpoint level.

  • !

    Immunogenicity in compounded-pharmacy preparations — where excipient, purity, and endotoxin specifications vary across 503A compounders — has no surveillance program. Anti-sermorelin antibody rates reported in the Geref clinical program do not necessarily generalize to compounded product.

  • !

    Drug–drug interactions in adults, particularly with corticosteroids (which blunt GH response) and with other axis-active peptides (ipamorelin, ibutamoren, tesamorelin), are not well-characterized in controlled trials.

  • !

    Whether sermorelin alters cardiovascular risk markers (lipids, visceral adiposity, blood pressure) in adults is unsettled — adjacent tesamorelin lipodystrophy trials are suggestive but not portable to sermorelin specifically.

  • !

    Current 503A compounding regulatory status is unstable — the molecule has an approved-drug history but no marketed product, which creates compounding ambiguity that the FDA has not definitively resolved as of the April 15, 2026 categories update.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Sermorelinand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • GHRH Analogs Explained: Sermorelin, Tesamorelin, and CJC-1295 With and Without DAC

    Dr. Kyle Gillett·MD, Family Medicine

    Walks through the four GHRH-analog generations, positions sermorelin as the short-acting pulsatility-preserving reference compound, and correctly notes that the 2008 Geref discontinuation was manufacturing-driven rather than safety-driven. Explicit that adult wellness claims exceed the adult-trial evidence.

    Verified credentials

  • Why Pulsatile GH Matters — The Physiology Case for Sermorelin

    Huberman Lab·PhD Neurobiology, Stanford

    Accurate on the Gαs/cAMP/PKA cascade and on why the 5–10 minute half-life preserves somatostatin feedback. Acknowledges that no controlled trial has measured sleep, body-composition, or cognitive endpoints with sermorelin in healthy adults.

    Verified credentials

  • Sermorelin Anti-Aging Clinic Protocol — My 6-Month Results

    Anonymous wellness influencer·Unverified

    Anecdotal before/after with no blinding, no control, no IGF-1 labs, and no DEXA. Common pattern of overstated benefit in the wellness-clinic / influencer layer. Do not weight against the Walker 2008 / Prakash 1999 peer-reviewed record.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 15 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

    Walker RF · Clinical Interventions in Aging · 2006

    Systematic reviewPMID 18031173
  2. [02]

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

    Prakash A, Goa KL · BioDrugs · 1999

    Systematic reviewDOI
  3. [03]

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (PMC full text)

    Walker RF · Clinical Interventions in Aging / PMC · 2006

    Systematic reviewDOI
  4. [04]

    Neuroendocrine control of growth hormone secretion

    Muller EE, Locatelli V, Cocchi D · Physiological Reviews · 1999

    Systematic reviewDOI
  5. [05]

    Growth hormone-releasing hormone receptor (GHRH-R) and its signaling

    Salvatori R, et al. · Reviews in Endocrine and Metabolic Disorders · 2025

    Systematic reviewDOI
  6. [06]

    Hypothalamic GHRH

    Salvatori R, et al. · Reviews in Endocrine and Metabolic Disorders · 2025

    Systematic reviewDOI
  7. [07]

    Targeting growth hormone function: strategies and therapeutic applications

    Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK · Signal Transduction and Targeted Therapy · 2019

    Systematic reviewDOI
  8. [08]

    Growth hormone secretagogues: history, mechanism of action, and clinical development

    Sinha DK, Balasubramanian A, Tatem AJ, et al. · JCSM Rapid Communications · 2020

    Systematic reviewDOI
  9. [09]

    Sermorelin — DrugBank monograph (DB00010)

    DrugBank Online · DrugBank · 2025

    RegistrationLink
  10. [10]

    Sermorelin — PubChem compound summary

    National Center for Biotechnology Information · PubChem · 2025

    RegistrationLink
  11. [11]

    Sermorelin — IUPHAR/BPS Guide to PHARMACOLOGY (ligandId 6998)

    IUPHAR/BPS · Guide to PHARMACOLOGY · 2025

    RegistrationLink
  12. [12]

    Sermorelin — FDA approval history, Geref discontinuation, molecular profile

    Wikipedia contributors · Wikipedia · 2026

    Systematic reviewLink
  13. [13]

    USADA athlete advisory — sermorelin and GHRH analogs

    U.S. Anti-Doping Agency · USADA Spirit of Sport · 2024

    RegulatoryLink
  14. [14]

    WADA 2026 Prohibited List (in force January 1, 2026) — Section S2.2 GHRHs and GHRH agonists

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink
  15. [15]

    FDA 503A Bulk Drug Substances Categories — April 15, 2026 Update

    U.S. Food and Drug Administration · FDA · 2026

    RegulatoryLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

CJC-1295

The long-acting DAC-conjugated descendant of the sermorelin backbone. Same receptor, opposite pharmacokinetic strategy — sermorelin preserves pulsatile physiology, CJC-1295 DAC replaces it with tonic elevation. Direct comparator and the most common alternative in the same clinical niche.

Read its grades

Compare

Ipamorelin

Most commonly stacked with sermorelin in research and off-label practice. Complementary mechanism — ipamorelin activates GHS-R1a (Gαq, ghrelin-receptor arm), sermorelin activates GHRH-R (Gαs) — both drive pulsatile GH release through independent receptor systems.

Read its grades

Compare

BPC-157

Frequently co-administered in research-chemical practice for recovery protocols. No shared mechanism with sermorelin, but the two are commonly discussed together in the same off-label conversations; BPC-157 is graded on its own evidence base.

Read its grades

Where to research further

Looking for Sermorelin
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →